New drug aims to hunt down lingering cancer after treatment
NCT ID NCT05414032
Summary
This study is testing an investigational drug called AZD2936 to see if it can clear tiny traces of leftover cancer and prevent the disease from returning. It is for patients with high-risk, locally advanced head and neck cancer who have already finished their main treatment (like surgery or chemoradiation) but still have signs of residual cancer in their blood. The goal is to see if this extra treatment can improve outcomes by targeting the cancer before it grows back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCOREGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Canada
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.